Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20627557rdf:typepubmed:Citationlld:pubmed
pubmed-article:20627557lifeskim:mentionsumls-concept:C0033373lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C1335204lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C1418440lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C0179302lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:20627557lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:20627557pubmed:issue13lld:pubmed
pubmed-article:20627557pubmed:dateCreated2010-8-20lld:pubmed
pubmed-article:20627557pubmed:abstractTextA novel series of benzoazepin-2-ones were designed and synthesized targeting the PIF pocket of AGC protein kinases, among which a series of thioether-linked benzoazepin-2-ones were discovered to bind to the PIF pocket of 3-phosphoinositide-dependent kinase-1 (PDK1), and to displace the PIF peptide with an EC(50) values in the lower micromolar range. The structure-activity relationships (SARs) of the linker region, tail region, and distal region were explored to further optimize these novel binders which target the PIF pocket of PDK1. When tested in an in vitro PDK1 enzymatic assay using a peptide substrate, the benzodiazepin-2-ones increased the activity of the enzyme in a concentration-dependent fashion, indicating these compounds act as PDK1 allosteric activators. These new compounds may be further developed as therapeutic agents for the treatment of diseases where the PDK1-mediated AGC protein kinases are dysregulated.lld:pubmed
pubmed-article:20627557pubmed:languageenglld:pubmed
pubmed-article:20627557pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20627557pubmed:citationSubsetIMlld:pubmed
pubmed-article:20627557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20627557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20627557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20627557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20627557pubmed:statusMEDLINElld:pubmed
pubmed-article:20627557pubmed:monthJullld:pubmed
pubmed-article:20627557pubmed:issn1464-3405lld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:LiuYiYlld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:UnoTetsuoTlld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:HaoXueshiXlld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:GaoXiaoqiXlld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:GuXiang-juXJlld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:BussiereDirks...lld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:WeiLinyiLlld:pubmed
pubmed-article:20627557pubmed:authorpubmed-author:WarneRobertRlld:pubmed
pubmed-article:20627557pubmed:copyrightInfo2010 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:20627557pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20627557pubmed:day1lld:pubmed
pubmed-article:20627557pubmed:volume20lld:pubmed
pubmed-article:20627557pubmed:ownerNLMlld:pubmed
pubmed-article:20627557pubmed:authorsCompleteYlld:pubmed
pubmed-article:20627557pubmed:pagination3897-902lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:meshHeadingpubmed-meshheading:20627557...lld:pubmed
pubmed-article:20627557pubmed:year2010lld:pubmed
pubmed-article:20627557pubmed:articleTitleDesign and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.lld:pubmed
pubmed-article:20627557pubmed:affiliationGenomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.lld:pubmed
pubmed-article:20627557pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:20627557lld:chembl